BACKGROUND:Antiandrogen withdrawal is a potential therapeutic maneuver for patients with progressive prostate cancer. This study was designed to examine antiandrogen withdrawal effects within the context of a large multi-institutional prospective trial. METHODS: Eligibility criteria included progressive prostate adenocarcinoma despite combined androgen blockade. Eligible patients received prior initial treatment with an antiandrogen plus orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist. Patients were stratified according to type of antiandrogen, type of progression (prostate-specific antigen [PSA] or radiographic), presence or absence of metastatic disease, and priorLHRH agonist versus surgical castration. RESULTS:A total of 210 eligible and evaluable patients had a median follow-up of 5.0 years; 64% of patients previously receivedflutamide, 32% bicalutamide, and 3% nilutamide. Of the 210 patients, 21% of patients had confirmed PSA decreases of >or=50% (95% CI, 16% to 27%). No radiographic responses were recorded. Median progression-free survival (PFS) was 3 months (95% CI, 2 months to 4 months); however, 19% had 12-month or greater progression-free intervals. Median overall survival (OS) after antiandrogen withdrawal was 22 months (20 and 40 months for those with and without radiographic evidence of metastatic disease, respectively). Multivariate analyses indicated that longer duration of antiandrogen use, lower PSA at baseline, and PSA-only progression at study entry were associated with both longer PFS and OS. Longer antiandrogen use was the only significant predictor of PSA response. CONCLUSIONS: These data indicate a relatively modest rate of PSA response in patients who were undergoing antiandrogen withdrawal; however, PFS can be relatively prolonged (>or=1 year) in approximately 19% of patients. (c) 2008 American Cancer Society.
RCT Entities:
BACKGROUND: Antiandrogen withdrawal is a potential therapeutic maneuver for patients with progressive prostate cancer. This study was designed to examine antiandrogen withdrawal effects within the context of a large multi-institutional prospective trial. METHODS: Eligibility criteria included progressive prostate adenocarcinoma despite combined androgen blockade. Eligible patients received prior initial treatment with an antiandrogen plus orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist. Patients were stratified according to type of antiandrogen, type of progression (prostate-specific antigen [PSA] or radiographic), presence or absence of metastatic disease, and prior LHRH agonist versus surgical castration. RESULTS: A total of 210 eligible and evaluable patients had a median follow-up of 5.0 years; 64% of patients previously received flutamide, 32% bicalutamide, and 3% nilutamide. Of the 210 patients, 21% of patients had confirmed PSA decreases of >or=50% (95% CI, 16% to 27%). No radiographic responses were recorded. Median progression-free survival (PFS) was 3 months (95% CI, 2 months to 4 months); however, 19% had 12-month or greater progression-free intervals. Median overall survival (OS) after antiandrogen withdrawal was 22 months (20 and 40 months for those with and without radiographic evidence of metastatic disease, respectively). Multivariate analyses indicated that longer duration of antiandrogen use, lower PSA at baseline, and PSA-only progression at study entry were associated with both longer PFS and OS. Longer antiandrogen use was the only significant predictor of PSA response. CONCLUSIONS: These data indicate a relatively modest rate of PSA response in patients who were undergoing antiandrogen withdrawal; however, PFS can be relatively prolonged (>or=1 year) in approximately 19% of patients. (c) 2008 American Cancer Society.
Authors: G J Bubley; M Carducci; W Dahut; N Dawson; D Daliani; M Eisenberger; W D Figg; B Freidlin; S Halabi; G Hudes; M Hussain; R Kaplan; C Myers; W Oh; D P Petrylak; E Reed; B Roth; O Sartor; H Scher; J Simons; V Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: Susan Halabi; Eric J Small; Philip W Kantoff; Michael W Kattan; Ellen B Kaplan; Nancy A Dawson; Ellis G Levine; Brent A Blumenstein; Nicholas J Vogelzang Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Eric J Small; Susan Halabi; Nancy A Dawson; Walter M Stadler; Brian I Rini; Joel Picus; Preston Gable; Frank M Torti; Ellen Kaplan; Nicholas J Vogelzang Journal: J Clin Oncol Date: 2004-03-15 Impact factor: 44.544
Authors: Tracy Proverbs-Singh; Jarett L Feldman; Michael J Morris; Karen A Autio; Tiffany A Traina Journal: Endocr Relat Cancer Date: 2015-02-26 Impact factor: 5.678
Authors: Betsan M Thomas; Christian Smith; Jessica Evans; Michael R Button; Satish Kumar; Nachi Palaniappan; John Staffurth; Jacob S Tanguay; Jason F Lester Journal: Med Oncol Date: 2013-09-12 Impact factor: 3.064
Authors: David Lorente; Joaquin Mateo; Zafeiris Zafeiriou; Alan D Smith; Shahneen Sandhu; Roberta Ferraldeschi; Johann S de Bono Journal: Nat Rev Urol Date: 2015-01 Impact factor: 14.432
Authors: Joan Carles; Daniel Castellano; Miguel Ángel Climent; Pablo Maroto; Rafael Medina; Antonio Alcaraz Journal: Clin Transl Oncol Date: 2012-03 Impact factor: 3.405
Authors: Giuseppe Di Lorenzo; Carlo Buonerba; Riccardo Autorino; Sabino De Placido; Cora N Sternberg Journal: Drugs Date: 2010-05-28 Impact factor: 9.546
Authors: J Paul Monk; Susan Halabi; Joel Picus; Arif Hussain; George Philips; Ellen Kaplan; Tim Ahles; Lin Gu; Nicholas Vogelzang; William K Kelly; Eric J Small Journal: Cancer Date: 2011-12-16 Impact factor: 6.860